Chemomab Therapeutics Ltd. has taken a significant step in its corporate evolution by filing a preliminary proxy statement related to its merger with Scipher Medicine Corporation. This merger is poised to reshape Chemomab's operational landscape and expand its market capabilities in the pharmaceutical preparations industry.

On November 10, 2026, Chemomab submitted its filing to the Securities and Exchange Commission (SEC), outlining key details of the merger agreement originally established on July 7, 2026. The merger is set to combine Chemomab's existing operations with Scipher's innovative portfolio, aiming to enhance their collective market presence and product offerings.

Background

Chemomab Therapeutics Ltd. operates within the pharmaceutical preparations sector, classified under SIC code 2834. The company is publicly traded on the Nasdaq under the ticker symbol CMMB. Recent filings include a Schedule 13D on the same day as the proxy statement, indicating ongoing strategic movements within the company.

What the Filing Says

The filing serves as a supplement to the proxy statement and prospectus dated October 30, 2026, which was sent to shareholders ahead of a special meeting scheduled for December 4, 2026. This meeting will focus on voting to approve the merger with Scipher Medicine Corporation. The document states, "The Merger is expected to be completed in the first calendar quarter of 2027." This timeline suggests a swift progression towards finalizing the merger.

Impact

This merger will significantly impact Chemomab's shareholders and stakeholders, as it aims to consolidate resources and expertise. The agreement includes provisions for Scipher to purchase up to 932,203 American Depositary Shares (ADSs) from Chemomab, further indicating a financial commitment to the merger process. The anticipated integration of Scipher's business into Chemomab is expected to enhance their competitive edge in the pharmaceutical market.

What's Next

The next steps involve the upcoming special meeting where shareholders will vote on the merger proposal. The filing does not specify any additional actions beyond this meeting.